|
ES517193A0
(es)
|
1981-11-10 |
1983-12-01 |
Wellcome Found |
Un procedimiento para la preparacion de nuevos derivados de imidazo (4,5-c)piridina.
|
|
US4847256A
(en)
|
1986-10-16 |
1989-07-11 |
American Cyanamid Company |
4,5-dihydro and 4,5,6,7-tetrahydropyrazolo(1,5-A)-pyrimidines
|
|
AU650953B2
(en)
|
1991-03-21 |
1994-07-07 |
Novartis Ag |
Inhaler
|
|
US5728536A
(en)
|
1993-07-29 |
1998-03-17 |
St. Jude Children's Research Hospital |
Jak kinases and regulation of Cytokine signal transduction
|
|
US6136595A
(en)
|
1993-07-29 |
2000-10-24 |
St. Jude Children's Research Hospital |
Jak kinases and regulations of cytokine signal transduction
|
|
US5543523A
(en)
|
1994-11-15 |
1996-08-06 |
Regents Of The University Of Minnesota |
Method and intermediates for the synthesis of korupensamines
|
|
US5705625A
(en)
|
1994-12-15 |
1998-01-06 |
The Johns Hopkins University School Of Medicine |
Nucleic Acid Encoding novel protein tyrosine kinase
|
|
US7070972B1
(en)
|
1995-01-13 |
2006-07-04 |
The United States Of America As Represented By The Department Of Health And Human Services |
Janus family kinases and identification of immune modulators
|
|
EP0842195A1
(fr)
|
1995-07-06 |
1998-05-20 |
Zeneca Limited |
Inhibiteurs peptidiques de la fibronectine
|
|
US6248713B1
(en)
|
1995-07-11 |
2001-06-19 |
Biogen, Inc. |
Cell adhesion inhibitors
|
|
US7091020B1
(en)
|
1995-12-05 |
2006-08-15 |
Incyte Corporation |
Human Jak2 kinase
|
|
ID18494A
(id)
|
1996-10-02 |
1998-04-16 |
Novartis Ag |
Turunan pirazola leburan dan proses pembuatannya
|
|
US6235741B1
(en)
|
1997-05-30 |
2001-05-22 |
Merck & Co., Inc. |
Angiogenesis inhibitors
|
|
FR2791562B1
(fr)
|
1999-03-29 |
2004-03-05 |
Oreal |
Composition tinctoriale contenant une pyrazolo-[1,5-a]- pyrimidine et une polyaminopyrimidine monocyclique a titre de bases d'oxydation et un coupleur, et procedes de teinture
|
|
YU25500A
(sh)
|
1999-05-11 |
2003-08-29 |
Pfizer Products Inc. |
Postupak za sintezu analoga nukleozida
|
|
DE60022366T2
(de)
|
1999-07-02 |
2006-06-14 |
Eisai Co Ltd |
Kondensierte imidazolderivate und arzneimittel gegen diabetes mellitus
|
|
EA006227B1
(ru)
|
1999-12-10 |
2005-10-27 |
Пфайзер Продактс Инк. |
СОЕДИНЕНИЯ ПИРРОЛО[2,3-d]ПИРИМИДИНА
|
|
GB0028383D0
(en)
|
2000-11-21 |
2001-01-03 |
Novartis Ag |
Organic compounds
|
|
EP1241176A1
(fr)
|
2001-03-16 |
2002-09-18 |
Pfizer Products Inc. |
Dérivés de purine pour le traitement de l'ischémie
|
|
CA2470813A1
(fr)
|
2001-12-20 |
2003-07-03 |
Bayer Healthcare Ag |
Derives de 1,4-dihydro-1,4-diphenylpyridine
|
|
KR20040097375A
(ko)
|
2002-04-23 |
2004-11-17 |
시오노기 앤드 컴파니, 리미티드 |
피라졸로[1, 5-에이]피리미딘 유도체 및 이를 함유한엔에이디(피)에이취 산화효소 저해제
|
|
US8580782B2
(en)
|
2002-09-04 |
2013-11-12 |
Merck Sharp & Dohme Corp. |
Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
|
|
US7161003B1
(en)
|
2002-09-04 |
2007-01-09 |
Schering Corporation |
Pyrazolopyrimidines as cyclin dependent kinase inhibitors
|
|
US7129239B2
(en)
|
2002-10-28 |
2006-10-31 |
Pfizer Inc. |
Purine compounds and uses thereof
|
|
AU2003270701B2
(en)
|
2002-10-31 |
2009-11-12 |
Amgen Inc. |
Antiinflammation agents
|
|
AU2003299651A1
(en)
|
2002-12-11 |
2004-06-30 |
Merck And Co., Inc. |
Tyrosine kinase inhibitors
|
|
EP1615667A2
(fr)
|
2003-04-11 |
2006-01-18 |
Novo Nordisk A/S |
Therapie combinatoire utilisant un inhibiteur de 11beta-hydroxysteroide deshydrogenase de type 1 et agoniste du recepteur de glucocorticoides
|
|
US20070270408A1
(en)
|
2003-04-11 |
2007-11-22 |
Novo Nordisk A/S |
Pharmaceutical use of substituted pyrazolo[1,5-a]pyrimidines
|
|
WO2004089416A2
(fr)
|
2003-04-11 |
2004-10-21 |
Novo Nordisk A/S |
Polytherapie utilisant un inhibiteur de type 1 de la 11beta-hydroxysteroide deshydrogenase et un agent hypotenseur dans le traitement du syndrome metabolique et des troubles et maladies associes
|
|
WO2004089471A2
(fr)
|
2003-04-11 |
2004-10-21 |
Novo Nordisk A/S |
Utilisation pharmaceutique de pyrazolo[1,5-a]pyrimidines substituees
|
|
WO2005004810A2
(fr)
|
2003-07-02 |
2005-01-20 |
Merck & Co., Inc. |
Derives arylsulfonamide
|
|
TWI372050B
(en)
|
2003-07-03 |
2012-09-11 |
Astex Therapeutics Ltd |
(morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
|
|
SE0302487D0
(sv)
|
2003-09-18 |
2003-09-18 |
Astrazeneca Ab |
Novel compounds
|
|
GB0329214D0
(en)
|
2003-12-17 |
2004-01-21 |
Glaxo Group Ltd |
Novel compounds
|
|
US7306631B2
(en)
|
2004-03-30 |
2007-12-11 |
The Procter & Gamble Company |
Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
|
|
WO2005110477A2
(fr)
|
2004-04-09 |
2005-11-24 |
University Of South Florida |
Polytherapies pour le cancer et des angiopathies proliferantes
|
|
CA2565037A1
(fr)
|
2004-04-28 |
2005-11-10 |
Cv Therapeutics, Inc. |
Antagonistes du recepteur de l'adenosine a<sb>1</sb>
|
|
WO2006004702A1
(fr)
|
2004-06-25 |
2006-01-12 |
Amgen Inc. |
Triazols et indazols condenses convenant pour le traitement de maladies induites par les citokines et autres pathologies
|
|
ES2354824T3
(es)
|
2004-11-04 |
2011-03-18 |
Vertex Pharmaceuticals, Inc. |
Pirazolo[1,5-a]pirimidinas útiles como inhibidores de proteínas cinasas.
|
|
GB0502258D0
(en)
|
2005-02-03 |
2005-03-09 |
Argenta Discovery Ltd |
Compounds and their use
|
|
JP2009502734A
(ja)
|
2005-07-29 |
2009-01-29 |
アステラス製薬株式会社 |
Ｌｃｋ阻害剤としての縮合複素環
|
|
WO2007039797A1
(fr)
|
2005-10-03 |
2007-04-12 |
Pfizer Products Inc. |
Utilisation d'antagonistes du recepteur cannabinoide de type 1 pour traiter les inflammations et l'arthrite
|
|
CA2624882C
(fr)
*
|
2005-10-06 |
2014-05-20 |
Schering Corporation |
Pyrazolopyrimidines en tant qu'inhibiteurs de proteines kinases
|
|
CN101316847A
(zh)
|
2005-10-06 |
2008-12-03 |
先灵公司 |
用作蛋白激酶抑制剂的吡唑并(1,5a)嘧啶化合物
|
|
WO2007048064A2
(fr)
|
2005-10-21 |
2007-04-26 |
Exelixis, Inc. |
Aminopyrimidines en tant que modulateurs de caseine kinase ii (ck2)
|
|
WO2007065664A2
(fr)
|
2005-12-08 |
2007-06-14 |
Novartis Ag |
Acides pyrazolo[1,5-a]pyridine-3-carboxyliques utilises en tant qu’inhibiteurs de la ephb et vegfr2 kinase
|
|
US8541406B2
(en)
|
2006-02-07 |
2013-09-24 |
Nv Remynd |
Thiadiazole derivatives for the treatment of neurodegenerative diseases
|
|
TW200800997A
(en)
|
2006-03-22 |
2008-01-01 |
Astrazeneca Ab |
Chemical compounds
|
|
AR061793A1
(es)
|
2006-07-05 |
2008-09-24 |
Mitsubishi Tanabe Pharma Corp |
Compuesto de pirazolo[1,5-a] pirimidina y composicion farmaceutica
|
|
PE20080403A1
(es)
|
2006-07-14 |
2008-04-25 |
Amgen Inc |
Derivados heterociclicos fusionados y metodos de uso
|
|
US8217177B2
(en)
|
2006-07-14 |
2012-07-10 |
Amgen Inc. |
Fused heterocyclic derivatives and methods of use
|
|
KR20090075714A
(ko)
|
2006-10-30 |
2009-07-08 |
노파르티스 아게 |
소염제로서의 헤테로시클릭 화합물
|
|
CA2670083A1
(fr)
|
2006-11-20 |
2008-05-29 |
Alantos Pharmaceuticals Holding, Inc. |
Inhibiteurs de metalloprotease heterobicycliques
|
|
WO2009017954A1
(fr)
|
2007-08-01 |
2009-02-05 |
Phenomix Corporation |
Inhibiteurs de kinase jak2
|
|
WO2009047359A1
(fr)
|
2007-10-12 |
2009-04-16 |
Ingenium Pharmaceuticals Gmbh |
Inhibiteurs de protéine kinases
|
|
ES2734288T3
(es)
|
2007-11-28 |
2019-12-05 |
Dana Farber Cancer Inst Inc |
Inhibidores de miristato de moléculas pequeñas de Bcr-abl y métodos de uso
|
|
US8642660B2
(en)
|
2007-12-21 |
2014-02-04 |
The University Of Rochester |
Method for altering the lifespan of eukaryotic organisms
|
|
KR20110033223A
(ko)
|
2008-06-20 |
2011-03-30 |
제넨테크, 인크. |
트리아졸로피리딘 ｊａｋ 억제제 화합물 및 방법
|
|
US8252791B2
(en)
|
2008-08-13 |
2012-08-28 |
Jenrin Discovery, Inc. |
Purine compounds as cannabinoid receptor blockers
|
|
CN102271515B
(zh)
*
|
2008-10-31 |
2014-07-02 |
健泰科生物技术公司 |
吡唑并嘧啶jak抑制剂化合物和方法
|
|
WO2010063487A1
(fr)
|
2008-12-05 |
2010-06-10 |
Merz Pharma Gmbh & Co. Kgaa |
Pyrazolopyrimidines, procédé pour leur préparation et leur utilisation comme médicament
|
|
CN102325765B
(zh)
|
2009-02-06 |
2014-12-24 |
杨森制药公司 |
作为γ-分泌酶调节剂的取代的双环杂环化合物
|
|
TWI461425B
(zh)
|
2009-02-19 |
2014-11-21 |
Janssen Pharmaceuticals Inc |
作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類
|
|
UA110324C2
(en)
|
2009-07-02 |
2015-12-25 |
Genentech Inc |
Jak inhibitory compounds based on pyrazolo pyrimidine
|
|
AR077468A1
(es)
|
2009-07-09 |
2011-08-31 |
Array Biopharma Inc |
Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
|
|
NZ598907A
(en)
|
2009-10-20 |
2014-03-28 |
Cellzome Ltd |
Heterocyclyl pyrazolopyrimidine analogues as jak inhibitors
|
|
JP2013522267A
(ja)
|
2010-03-17 |
2013-06-13 |
エフ．ホフマン−ラ ロシュ アーゲー |
イミダゾピリジン化合物、組成物、および使用法
|
|
MX2012012328A
(es)
|
2010-04-30 |
2013-05-06 |
Cellzome Ltd |
Compuestos pirazol como inhibidores de jak.
|
|
CN102985426B
(zh)
|
2010-07-13 |
2015-10-07 |
弗·哈夫曼-拉罗切有限公司 |
作为irak4调节剂的吡唑并[1,5a]嘧啶和噻吩并[3,2b]嘧啶衍生物
|
|
WO2012075393A2
(fr)
|
2010-12-02 |
2012-06-07 |
President And Fellows Of Harvard College |
Activateurs de la dégradation protéasomique et leurs utilisations
|
|
US9169260B2
(en)
*
|
2011-03-22 |
2015-10-27 |
Merck Sharp & Dohme Corp. |
Amidopyrazole inhibitors of interleukin receptor-associated kinases
|
|
US8575336B2
(en)
|
2011-07-27 |
2013-11-05 |
Pfizer Limited |
Indazoles
|
|
ES2666353T3
(es)
|
2012-09-06 |
2018-05-04 |
Bristol-Myers Squibb Company |
Inhibidores de JAK3 de imidazopiridazina y su uso para el tratamiento de enfermedades inflamatorias y autoinmunitarias
|
|
US9409893B2
(en)
|
2012-11-09 |
2016-08-09 |
Jacobus Pharmaceutical Company, Inc. |
Heteroaryl derivatives and uses thereof
|
|
WO2015006181A1
(fr)
|
2013-07-11 |
2015-01-15 |
Merck Sharp & Dohme Corp. |
Inhibiteurs amidopyrazole substitués de kinases associées aux récepteurs de l'interleukine (irak -4)
|
|
WO2015068856A1
(fr)
|
2013-11-08 |
2015-05-14 |
Takeda Pharmaceutical Company Limited |
Pyrazole pour le traitement de troubles auto-immuns
|
|
WO2015073267A1
(fr)
|
2013-11-15 |
2015-05-21 |
Calitor Sciences, Llc |
Composés hétéroaryle substitués et méthodes d'utilisation
|
|
KR20170008850A
(ko)
|
2014-05-23 |
2017-01-24 |
피브로-애니멀 헬스 코포레이션 |
배합물, 조성물, 및 배합물 또는 조성물의 동물로의 투여 방법
|
|
JO3701B1
(ar)
|
2014-05-23 |
2021-01-31 |
Regeneron Pharma |
مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
|
|
EA032488B1
(ru)
*
|
2014-05-23 |
2019-06-28 |
Ф. Хоффманн-Ля Рош Аг |
Соединения 5-хлор-дифторметоксифенилпиразолопиримидина, представляющие собой ингибиторы янус-киназы
|
|
CN107001379B
(zh)
|
2014-11-06 |
2022-11-01 |
Bial研发投资股份有限公司 |
取代的吡唑并[1,5-a]嘧啶以及它们在治疗医学障碍中的用途
|
|
WO2016144846A1
(fr)
|
2015-03-12 |
2016-09-15 |
Merck Sharp & Dohme Corp. |
Inhibiteurs de l'activité d'irak4 à base de pyrazolopyrimidine
|
|
WO2016144848A1
(fr)
|
2015-03-12 |
2016-09-15 |
Merck Sharp & Dohme Corp. |
Inhibiteurs de pyrrolotriazine de l'activité d'irak4
|
|
US10155765B2
(en)
|
2015-03-12 |
2018-12-18 |
Merck Sharp & Dohme Corp. |
Carboxamide inhibitors of IRAK4 activity
|
|
US10040798B2
(en)
|
2015-03-12 |
2018-08-07 |
Merck Sharp & Dohme Corp. |
Pyrrolopyridazine inhibitors of IRAK4 activity
|
|
TW201720828A
(zh)
|
2015-11-23 |
2017-06-16 |
赫孚孟拉羅股份公司 |
治療性化合物及組合物以及其使用方法
|
|
JP6936236B2
(ja)
|
2016-02-18 |
2021-09-15 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
治療化合物、組成物及びその方法の使用
|
|
AU2017385543A1
(en)
|
2016-12-29 |
2019-05-23 |
F. Hoffmann-La Roche Ag |
Pyrazolopyrimidine compounds and methods of use thereof
|
|
EP3596072B1
(fr)
|
2017-03-14 |
2022-06-22 |
F. Hoffmann-La Roche AG |
Composés de pyrazolochlorophényle, compositions et méthodes d'utilisation associées
|
|
WO2018215389A1
(fr)
*
|
2017-05-22 |
2018-11-29 |
F. Hoffmann-La Roche Ag |
Composés thérapeutiques, compositions et procédés d'utilisation associés
|
|
US20180334465A1
(en)
|
2017-05-22 |
2018-11-22 |
Genentech, Inc. |
Therapeutic compounds and compositions, and methods of use thereof
|